Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells by Hutcheson, Iain R et al.
Open Access
Available online http://breast-cancer-research.com/content/9/4/R50
Page 1 of 14
(page number not for citation purposes)
Vol 9 No 4 Research article
Heregulin β1 drives gefitinib-resistant growth and invasion in 
tamoxifen-resistant MCF-7 breast cancer cells
Iain R Hutcheson1, Janice M Knowlden1, Steve E Hiscox1, Denise Barrow1, Julia MW Gee1, 
John F Robertson2, Ian O Ellis2 and Robert I Nicholson1
1Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 
3XF, UK
2Professorial Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
Corresponding author: Iain R Hutcheson, hutchesonir@cf.ac.uk
Received: 23 Jan 2007 Revisions requested: 15 Apr 2007 Revisions received: 18 Jul 2007 Accepted: 8 Aug 2007 Published: 8 Aug 2007
Breast Cancer Research 2007, 9:R50 (doi:10.1186/bcr1754)
This article is online at: http://breast-cancer-research.com/content/9/4/R50
© 2007 Hutcheson et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Resistance to anti-epidermal growth factor
receptor (anti-EGFR) therapies is an emerging clinical problem.
The efficacy of anti-EGFR therapies can be influenced by the
presence of heregulins (HRGs), which can bind erbB3/4
receptors and can activate alternative signalling pathways. In the
present study we have examined whether HRG signalling can
circumvent EGFR blockade in an EGFR-positive tamoxifen-
resistant MCF-7 (Tam-R) breast cancer cell line.
Methods Tam-R cells, incubated with the selective EGFR
tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839), were
exposed to HRGβ1 and the effects on erbB receptor
dimerization profiles and on activation of associated
downstream signalling components were assessed by
immunoprecipitation, western blotting and
immunocytochemistry. The effects of HRGβ1 on gefitinib-
treated Tam-R cell growth and invasion were also examined, and
HRGβ1 expression levels were assessed in breast cancer
tissue by immunohistochemistry to address the potential clinical
relevance of such a resistance mechanism.
Results In Tam-R cells, HRGβ1 promoted erbB3/erbB2 and
erbB3/EGFR heterodimerization, promoted ERK1/2 and AKT
pathway activation and increased cell proliferation and invasion.
Gefitinib prevented HRGβ1-driven erbB3/EGFR
heterodimerization, ERK1/2 activation and Tam-R cell
proliferation, but HRGβ1-driven erbB3/erbB2
heterodimerization, AKT activation and Tam-R cell invasion were
maintained. A combination of gefitinib and the
phosphatidylinositol 3-kinase inhibitor LY294002 effectively
blocked HRGβ1-mediated intracellular signalling activity,
growth and invasion in Tam-R cells. Similarly, targeting erbB2
with trastuzumab in combination with gefitinib in Tam-R cells
reduced HRGβ1-induced erbB2 and ERK1/2 activity; however,
HRGβ1-driven AKT activity and cell growth were maintained
while cell invasion was significantly enhanced with this
combination. In clinical tissue all samples demonstrated
cytoplasmic tumour epithelial HRGβ1 protein staining, with
expression correlating with EGFR positivity and activation of
both AKT and ERK1/2.
Conclusion HRGβ1 can overcome the inhibitory effects of
gefitinib on cell growth and invasion in Tam-R cells through
promotion of erbB3/erbB2 heterodimerization and activation of
the phosphatidylinositol 3-kinase/AKT signalling pathway. This
may have implications for the effectiveness of anti-EGFR
therapies in breast cancer as HRGβ1 is enriched in many
EGFR-positive breast tumours.
Introduction
The epidermal growth factor receptor (EGFR), a member of
the erbB proto-oncogene family of receptor tyrosine kinases,
which also includes erbB2, erbB3 and erbB4, is a transmem-
brane glycoprotein composed of an extracellular ligand-bind-
ing domain and an intracellular domain containing tyrosine
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protein kinase; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; PI3K = phosphatidylinositol 3-kinase; Tam-R = tamoxifen-resist-
ant MCF-7; TBS = Tris-buffered saline; TGFα = transforming growth factor alpha.Breast Cancer Research    Vol 9 No 4    Hutcheson et al.
Page 2 of 14
(page number not for citation purposes)
kinase activity [1,2]. Activation of EGFR results from binding of
epidermal growth factor-related growth factors, such as epi-
dermal growth factor, transforming growth factor alpha
(TGFα) and amphiregulin, which induce receptor homodimer-
ization and/or heterodimerization with other members of the
erbB receptor family [2]. No direct ligand for erbB2 has yet
been identified; however, erbB2 plays a central role in erbB
receptor function as it is the preferred dimerization partner for
all other erbB family members [3,4].
Receptor dimerization stimulates the intrinsic receptor tyrosine
kinase activity and promotes autophosphorylation of tyrosine
residues within the cytoplasmic domain of the receptor. These
phosphotyrosine residues provide docking sites for a variety of
adaptor proteins and enzymes involved in the recruitment and
activation of downstream intracellular signalling cascades,
including the mitogen-activated protein kinase (MAPK) and
phosphatidylinositol-3 kinase (PI3K) pathways [2]. These sig-
nalling cascades can promote proliferation, angiogenesis and
invasion, and can inhibit apoptosis, key mechanisms underly-
ing tumour growth and progression [5]. This oncogenic poten-
tial in conjunction with the aberrant expression and/or
activation of EGFR, which has been reported in a range of
human malignancies including breast cancer, provides a
strong rationale for targeting this growth factor receptor [6,7].
A number of agents targeting EGFR have now been devel-
oped and include the monoclonal antibody cetuximab, which
targets the extracellular ligand-binding domain of EGFR, and
the small molecule tyrosine kinase inhibitors gefitinib (Iressa,
ZD1839) and erlotinib (Tarceva, OSI-774), which competi-
tively block binding of ATP to the tyrosine kinase domain of the
receptor [8]. These compounds are proven effective antitu-
mour agents as monotherapies in both the preclinical and clin-
ical setting, and have been shown to enhance the effects of
cytotoxic agents and radiation when utilized in combination
with these conventional chemotherapies [8-10]. Conse-
quently, cetuximab, gefitinib and erlotinib have now all gained
approval for cancer treatment in the clinic. Recent findings
from clinical trials, however, have revealed that only a small
cohort of patients have derived significant benefit from these
therapies, with both de novo and acquired resistance to these
agents being evident [11-13]. Furthermore, evidence of resist-
ance to anti-EGFR therapies has now also been reported in
preclinical cell models [12,13]. A number of potential resist-
ance mechanisms have now been implicated, including recep-
tor mutation, loss of downstream effector components and
activation of alternative oncogenic signalling pathways
[12,14].
A common resistance mechanism to anti-EGFR therapies
identified by a number of research groups in preclinical cancer
models of the colon, the breast, the prostate and the brain
involves activation of the PI3K/AKT signalling pathway either
as a consequence of the loss of phosphatase and tensin
homologue or of increased insulin-like growth factor type 1
receptor activity [12,15-19]. PI3K/AKT signalling pathway
activity can also be driven through activation of erbB3 and
erbB4 receptors via their ability to directly recruit the p85 reg-
ulatory subunit of PI3K [20,21]. erbB3 and erbB4 are recep-
tors for the neuregulin family of growth factors, which consists
of NRG1 or heregulin (HRG), NRG2, NRG3 and NRG4.
These neuregulins have been shown to potently drive cell pro-
liferation, survival, motility and invasion in a range of cancer cell
types [22]. In breast cancer, HRG has been reported to be
detectable in clinical tissue [23,24] and has been identified as
a mitogenic and proinvasive factor in preclinical studies both
in vitro and in vivo [25-31].
Previous studies from our group have established that growth
of a tamoxifen-resistant MCF-7 (Tam-R) breast cancer cell line
is driven by the autocrine release of the epidermal growth fac-
tor-like ligand amphiregulin and activation of the EGFR/MAPK
signalling pathway [32-34]. Furthermore, activation of this sig-
nal transduction mechanism has also been implicated in the
increased motility and invasiveness observed in this cell line
[35]. Both Tam-R cell growth and invasion are therefore sensi-
tive to the inhibitory actions of the selective EGFR tyrosine
kinase inhibitor gefitinib [32-35]. In the present study we have
investigated whether HRGβ1 can overcome the inhibitory
effects of gefitinib on Tam-R cell growth and invasion, and we
have examined the potential pathways activated by this erbB3/
4 ligand. We have further assessed the expression levels of
HRGβ1 in a series of 77 primary breast cancer samples from
patients who had received no prior therapy to assess whether
such signalling may be important in the clinical setting.
Materials and methods
Cell culture
All tissue culture medium and constituents were purchased
from Gibco Europe Ltd. (Paisley, UK), and tissue culture plas-
tics were obtained from Nunc (Roskilde, Denmark). The
EGFR-positive tamoxifen-resistant Tam-R cell line was devel-
oped by continually exposing MCF-7 breast cancer cells, a gift
from AstraZeneca Pharmaceuticals (Cheshire UK), to 4-
hydroxytamoxifen (100 nM) over a period of 6 months [32].
The Tam-R cell line was maintained in phenol-red-free RPMI
medium containing 5% charcoal-stripped steroid-depleted
FCS, penicillin–streptomycin (10 IU/ml–10 μg/ml), fungizone
(2.5 μg/ml), glutamine (4 mM) and 4-hydroxytamoxifen (100
nM in ethanol). This cell line was maintained at 37°C in a
humidified 5% CO2 atmosphere.
Immunoprecipitation and western blotting
Experimental cell culture
The Tam-R cell line was grown for 4 days before being trans-
ferred into phenol-red/steroid-free, serum growth factor-free
DCCM (Biosynergy (Europe), Cambridge, UK) for 24 hours.
The cells were then lysed for protein or mRNA analysis. To
examine the effects of pharmacological agents, cells wereAvailable online http://breast-cancer-research.com/content/9/4/R50
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lysed following a further incubation in DCCM supplemented
with either HRGβ1 (10 ng/ml in ethanol; Sigma, Poole, UK) for
10 minutes, gefitinib (1 μM in ethanol; AstraZeneca, Maccles-
field, UK) for 1 hour, trastuzumab (100 nM in water; Roche
Pharmaceuticals, Penzberg, Germany) for 7 days or LY
294002 (10 μM in water; Affiniti Research Products Ltd, Exe-
ter, UK) for 1 hour, or combinations of these treatments. Con-
trols were incubated for the same periods of time with the
appropriate vehicle. All experiments were performed at least
three times.
Cell lysis
Cells were washed three times with PBS and lysed using ice-
cold lysis buffer (for composition, see Knowlden and col-
leagues [32]. The cellular contents were transferred to micro-
fuge tubes, clarified by centrifugation at 13,000 rpm for 15
minutes at 4°C and the supernatant aliquots stored at -20°C
until required. Total protein concentrations were determined
using the DC BioRad protein assay kit (BioRad Labs Ltd,
Hemel Hempstead, UK).
Immunoprecipitation
Cell lysates containing 1 mg protein were immunoprecipitated
using 1 μg specific total EGFR and erbB3 antibody and were
incubated on ice for 1 hour. Then 30 μl protein A agarose
(Insight Biotechnology Ltd, Wembley, UK) was added to the
mixture and the mixture was inverted frequently by hand for a
further 2 hours. The immune complex was centrifuged at
3,000 rpm at 4°C for 5 minutes and was washed with ice-cold
lysis buffer. This procedure was repeated twice and the result-
ant pellet was resuspended in 20 μl Laemmli sample loading
buffer containing 0.01 M dithiothreitol. Samples were heated
to 100°C for 5 minutes to release the bound proteins prior to
gel loading.
Western blotting
Protein samples from total cell lysates (20 μg) were subjected
to electrophoresis separation on a 7.5% polyacrylamide gel
and were transblotted onto a nitrocellulose membrane (Sch-
leicher and Schuell, Dassel, Germany). Blots were blocked at
room temperature for 1 hour in 5% skimmed milk powder
made up in Tris-buffered saline (TBS)–Tween 20 (0.05%),
and were incubated for a minimum of 1 hour in primary anti-
body diluted 1/40,000 for β-actin (reference control) or 1/
1,000 for EGFR, erbB2, erbB3, erbB4, AKT and ERK1/2
MAPK in 1% marvel/TBS–Tween. The membranes were
washed three times in TBS–Tween and then incubated for 1
hour with the required secondary IgG horseradish peroxidase-
labelled donkey anti-rabbit or sheep anti-mouse (Amersham
Biosciences UK Ltd, Buckinghamshire, UK), diluted 1/20,000
in 1% marvel/TBS–Tween. Detection was performed using
West Dura chemiluminescent detection reagents (Pierce and
Warriner Ltd, Chester, UK).
The antibodies used were total EGFR (SC-03) erbB2 (SC-
284), erbB3 (SC-285) and erbB4 (SC-283) (Insight Biotech-
nology Ltd), anti-phospho-erbB2 (pY1248, 2247), anti-phos-
pho-EGFR (pY1068, 2234), total AKT (9272), phospho-AKT
(pS473, 9271), total ERK1/2 (9102) and phospho-ERK1/2
(pT202/pY204, 9101) (New England Biolabs, Hitchin, Hert-
fordshire, UK), and β-actin (AC-15) (Sigma). These antibodies
were selected as they have been demonstrated to be mono-
specific and do not cross-react with other family members.
Results were scanned using a BioRad model GS-690 Imaging
Densitometer (BioRad Labs Ltd, Hemel Hempstead, Hertford-
shire, UK).
Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from Tam-R breast cells and DU145
prostate cancer cells grown under basal conditions, using an
RNA isolator kit (Genosys Biotech Inc., Cambridge, UK), and
1 μg was reverse transcribed using standard conditions as
described previously [32]. Sterile water was also used, in
place of RNA, as a negative control for reverse transcription.
Resultant cDNA samples, reverse transcription negative con-
trol samples and sterile water (negative PCR control) samples
were amplified for 40 cycles using specific primers for HRGβ1
and the conditions were optimized as described previously
[32].
The primers used for HRGβ1 were designed manually, and the
specificity was checked with the EMBL-GenBank database
software using the Blast program. The HRGβ1 primers were
5'-GAT CAT CAC TGG TAT GCC AG and 3'-TAA ATT CAA
TCC CAA GAT GC.
Cell invasion assay
Cell invasion was quantified using a modification of a previ-
ously described method [36]. Briefly, ThinCert tissue cell cul-
ture inserts (31.2 mm2 culture surface, 8.0 μm pore size;
Greiner Bio-One, Gloucester, UK) were coated with Matrigel
(0.4 μg/ml) overnight at room temperature in a sterile tissue
culture hood. After rehydrating the matrix with serum-free
RPMI for 1 hour at 37°C, cells were seeded into the chambers
at 5 × 104 cells/well, while 500 μl culture medium were added
to the outside of the well. Cells were incubated with either
HRGβ1 (10 ng/ml), gefitinib (1 μM), trastuzumab (100 nM),
LY 294002 (10 μM) or combinations of these treatments.
Controls were incubated for the same periods of time with the
appropriate vehicle. Inserts were cultured at 37°C for 72
hours, after which the noninvasive cells and Matrigel were
removed from the inside of the wells with a cotton swab. After
fixation of the invaded cells with 4% formaldehyde, porous
membranes were removed from the invasion chamber using a
scalpel blade and were mounted onto glass microscope slides
using Vectashield (Molecular Probes, Eugene, OR, USA) con-
taining the nuclear stain 4'-6-diamidino-2-phenylindole. Cell
invasion was quantified with a fluorescent microscope by
viewing five separate fields per membrane at 20-timesBreast Cancer Research    Vol 9 No 4    Hutcheson et al.
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magnification and counting the number of cells (identified by
stained cell nuclei) in each field. Data were then plotted as
mean cells per field ± standard deviation.
Cell proliferation
Cell monolayers were grown for 7 days in serum growth fac-
tor-free DCCM in the presence of either HRGβ1 (10 ng/ml),
gefitinib (1 μM), trastuzumab, (100 nM), LY 294002 (10 μM),
combinations of these agents or the appropriate vehicle con-
trol. Cell population growth was then evaluated by means of
trypsin dispersion of the cell monolayers and the cell number
was measured using a Coulter counter (Beckman, Luton, UK).
All experiments were performed in triplicate.
Clinical tissue and immunocytochemistry
Clinical samples
A series of 77 primary tumours were excised from patients
with histologically proven breast cancer presenting for surgery
at the City Hospital, Nottingham during the period 1984–
1987. Representative tissue samples from these 77 samples
were fixed routinely in 4% formal saline and embedded in par-
affin. No patient had previously received any form of adjuvant
endocrine or cytotoxic therapy. Parallel data for the histologic
grade of malignancy, the menopausal status, the site of dis-
ease and the Ki-67 index, together with information on nuclear
oestrogen receptor, membrane EGFR, membrane erbB2,
membrane erbB3, cytoplasmic TGFα and nuclear phosphor-
ylated MAPK protein, were available for these samples (Table
1). This research was approved by Nottingham Research Eth-
ics Committee 2 under the title 'Development of a molecular
genetic classification of breast cancer' (C2020313).
Immunocytochemistry
Paraffin wax sections from each tumour sample from the series
of 77 patients were dewaxed using xylene treatment and were
then rehydrated through graded ethanols to PBS. Endog-
enous peroxidases were destroyed by immersing the sections
in 3%hydrogen peroxide prepared in methanol, followed by
rinsing with distilled water. Prior to blocking with either BSA or
goat serum, antigen retrieval was achieved either by microwav-
ing/pressure cooking in 0.01 M sodium citrate buffer or by
enzyme digestion with 0.02% pronase E (Sigma). Slides were
thoroughly rinsed either under running tap water or in PBS to
terminate retrieval of PBS. The assays used in these studies
followed previously described protocols for immunostaining of
TGFα, total EGFR, total erbB2, total erbB3 and phosphor-
ylated ERK1/2 [37-39,41]. Cytoplasmic HRGβ1, phosphor-
ylated membrane erbB2 and nuclear AKT immunostaining was
carried out as detailed below.
Slides were incubated overnight in a sealed humidity chamber
at room temperature either with rabbit anti-HRGβ1 antibody
raised to a synthetic peptide from the COOH-terminal third of
the epidermal growth factor homology region of human
HRGβ1 protein (a kind gift from WJ Gullick, [42]) at 1/15 in
5% BSA/PBS, with rabbit anti-phospho-erbB2 antibody (06–
229; Upstate Ltd, Chandlers Ford, Hampshire, UK) at 1/350
in PBS or with anti-phospho-AKT (New England Biolabs) at 1/
50 in PBS. Following PBS rinsing and washing in DPC buffer
(Euro/DPC Ltd., Llanberis, UK), all slides were covered for 2
hours with a 1/50 dilution of a goat anti-rabbit IgG peroxidase
conjugate (A4914; Sigma). An omission of primary antibody
was used as the control. Further confidence in the specificity
of the assays was derived from control sections of each clini-
cal sample that were incubated with a dilution of primary anti-
body matched to that of the paired tests but preabsorbed for
5 hours with appropriate blocking peptide (one part anti-
body:three parts peptide). The slides were then rinsed in PBS
and DPC buffer. Signal detection was carried out for 10 min-
utes with freshly prepared diaminobenzidine tetrahydrochlo-
ride/hydrogen peroxide chromogen (Abbott Diagnostics ER-
ICA kit, Maidenhead, UK). The resultant signal was enhanced
for 7 minutes using 0.5%CuSO4·5H2O prepared in 0.85%
NaCl and the slides were lightly counterstained using 0.5%
methyl green. The slides were then dehydrated briefly before
air-drying and clearing in xylene and a coverslip was posi-
tioned over the section using DPX mountant.
Cytoplasmic HRGβ1, membrane-phosphorylated erbB2 and
nuclear-phosphorylated AKT immunostaining were assessed
by two personnel using a dual-viewing attachment to an Olym-
pus BH-2 light microscope (Jencons Ltd, Leighton Buzzard,
Bedfordshire, UK). Estimates of the intensity of staining and
the percentage of cells positively stained were determined
using a minimum evaluation of 2,000 tumour cells per cover-
slip. These data were used to construct an H-score or a field
staining index for each marker as described previously [43]
Statistics
For immunocytochemical analysis of clinical samples, the
Mann–Whitney U test was employed to compare median val-
ues between certain groups. The Spearman rank correlation
test was also employed to determine the degree of association
between the protein H-scores of all examined variables. For
the Tam-R cell growth studies, overall differences between
control and treatment groups were examined by one-way anal-
ysis of variance. Direct comparisons between control and
treatment effects in Tam-R cells were determined using a Stu-
dent t test with the Bonferroni adjustment factor. Differences
were considered significant at the P < 0.05 level for all tests.
Results
HRGβ1, erbB3 and erbB4 expression
HRGβ1 mRNA could not be detected in Tam-R cells following
40 cycles of amplification; however, expression of this ligand
was detected at the mRNA level in DU145 prostate cancer
cells (positive control) (Figure 1a).
Western blotting and immunocytochemical studies demon-
strated high expression levels of erbB3 protein in the Tam-RAvailable online http://breast-cancer-research.com/content/9/4/R50
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cell line, with high levels of membrane staining being observed
in this cell line. Expression of erbB4, however, could barely be
detected by western blotting (Figure 1b) and by immunocyto-
chemistry (data not shown) in this cell line.
Under basal growth conditions, immunoprecipitation/western
blotting studies revealed that phosphorylated levels of erbB3
were detectable in Tam-R cells (Figure 2a). Furthermore, the
presence of low levels of phosphorylated erbB3/EGFR and
erbB3/erbB2 heterodimers could be discerned (Figure 2a).
Basal levels of phosphorylated AKT and ERK1/2 were also
Table 1
Clinicopathological parameters for the clinical tumour set
Number Percentage
Tumour grade
Grade 1 2 2.6
Grade 2 29 37.7
Grade 3 43 55.8
Not known 3 3.9
Oestrogen receptor status
Positive 46 59.7
Negative 31 40.3
Epidermal growth factor receptor (membrane) 
status
Positive 43 55.8
Negative 31 40.3
Not known 3 3.9
erbB2 (membrane) status
Positive 19 71.4
Negative 55 24.7
Not known 3 3.9
erbB3 (membrane) status
Positive 61 79.3
Negative 9 11.7
Not known 7 9.1
Menopausal status
Premenopausal 23 31.1
Postmenopausal 51 68.9
Not known 3 3.9
Site of disease
Locally advanced 29 39.2
Metastatic 45 60.8
Not known 3 3.9
Ki-67 index
01 0 1 3
<10 15 19.5
10–30 52 67.5Breast Cancer Research    Vol 9 No 4    Hutcheson et al.
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observed in the Tam-R cell line (Figure 2b). The high levels of
basal phosphorylated erbB2 (Figure 2b) are primarily a conse-
quence of EGFR/erbB2 heterodimerization and activation
(Figure 2c) that we have previously shown to occur under
basal growth conditions in this cell line [32].
Effects of gefitinib
Gefitinib (1 μM) treatment promoted the formation of EGFR/
erbB2 heterodimers, had no effect on levels of EGFR/erbB3
heterodimers and reduced erbB3/erbB2 heterodimers in the
Tam-R cell line (Figure 2a,c). Gefitinib treatment also reduced
basal phosphorylation levels of all heterodimers examined
(Figure 2a,c). This inactivation of erbB heterodimers was asso-
ciated with a reduction in basal EGFR, erbB2 and erbB3
phosphorylation levels in response to gefitinib in these cells
(Figure 2a,b). Gefitinib was without effect on the total EGFR,
erbB2 and erbB3 expression levels in this cell line (Figure
2a,b). Gefitinib treatment also potently inhibited basal ERK1/2
and AKT activity in both cell lines without exerting any effect on
total protein expression levels (Figure 2b).
As previously described, gefitinib was a potent inhibitor of
both basal cell growth and invasion in Tam-R cells [32,35],
reducing basal cell growth by approximately 75% at day 7 (P
< 0.01, n = 4) and reducing basal cell invasion by approxi-
mately 60% at day 3 (P < 0.01, n = 3) (Figure 3).
Effects of HRGβ1 in the absence and presence of 
gefitinib
Following treatment with HRGβ1 (10 ng/ml) the erbB3 recep-
tor activity was dramatically increased in Tam-R cells, with
HRGβ1 promoting activation of EGFR and erbB2 and
promoting the formation of both active erbB3/erbB2 and
erbB3/EGFR heterodimers in this cell line (Figure 4a,b). Under
these same conditions basal expression levels of phosphor-
ylated ERK1/2 and phosphorylated AKT were detectable in
Tam-R cells as determined by western blotting, and the activity
of both ERK1/2 and AKT were further increased following
treatment of the cells with HRGβ1 (Figure 4b). These
increases were not a consequence of increased total protein
expression since both total ERK1/2 and AKT expression levels
remained unchanged (Figure 4b).
In the presence of gefitinib, HRGβ1 was without effect on
EGFR activity and did not promote the formation of activated
erbB3/EGFR heterodimers in Tam-R cells. HRGβ1 was still
capable, however, of activating erbB2 and of promoting forma-
tion of active erbB3/erbB2 heterodimers in the presence of
the anti-EGFR agent in this cell line (Figure 4a,b). Furthermore,
following gefitinib treatment, HRGβ1 was without effect on
ERK1/2 activity whereas a HRGβ1-induced AKT activation
was still apparent (Figure 4b).
Growth of Tam-R cells was significantly enhanced following
HRGβ1 treatment, with an approximately 30% increase in pro-
liferation being observed on day 7 of treatment compared with
the control values (P < 0.01, n = 4; Figure 3). Similarly, Tam-
R cell invasion was also significantly increased following
HRGβ1 treatment, with approximately three times as many
Tam-R cells invading through the artificial basement mem-
brane following a 3-day treatment with this ligand (P < 0.001,
n  = 3; Figure 3). Gefitinib reduced Tam-R cell growth in
response to HRGβ1, although a substantial and significant
level of ligand-induced growth was still observed in the pres-
ence of this inhibitor (P < 0.05, n = 4; Figure 3). Gefitinib was
without effect on HRGβ1-induced Tam-R cell invasion (Figure
3).
Figure 1
Expression of HRGβ1, erbB3 and erbB4 in tamoxifen-resistant MCF-7  cells Expression of HRGβ1, erbB3 and erbB4 in tamoxifen-resistant MCF-7 
cells. (a) RT-PCR analysis of basal HRGβ1 mRNA in DU145 prostate 
and tamoxifen-resistant MCF-7 (Tam-R) breast cancer cells. (b) Total 
erbB3 and erbB4 protein expression in Tam-R cells by western blotting 
and immunocytochemistry (original magnification, ×20). β-Actin protein 
expression was also assessed to demonstrate equivalent sample load-
ing. Tamoxifen was present in Tam-R media. Data are representative of 
at least three separate experiments.Available online http://breast-cancer-research.com/content/9/4/R50
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Effect of trastuzumab alone and in combination with 
gefitinib
As previously reported [32], treatment of Tam-R cells with the
anti-erbB2 monoclonal antibody trastuzumab (100 nM)
reduced levels of basal phosphorylated and total erbB2, and
this reduction was associated with a reduction in basal AKT
and ERK1/2 activity and a significant inhibition of proliferative
activity in these cells (P < 0.01, n = 6; Figures 5a and 6a).
Trastuzumab was without effect, however, on the basal inva-
sive capacity of Tam-R cells (Figure 6b).
The inhibitory effect of trastuzumab on cell signalling activity
was overcome by HRGβ1, which promoted phosphorylation
of erbB2, AKT and ERK1/2 in the presence of this antibody
(Figure 5a). There was consequently no effect of trastuzumab
on HRGβ1-induced Tam-R cell growth and invasion (Figure
6a,b).
In combination with gefitinib, trastuzumab treatment reduced
HRGβ1-induced erbB2 and ERK1/2 activity but had only a
minimal effect on AKT phosphorylation. This effect of
trastuzumab and gefitinib in combination on the intracellular
signalling activity was associated with a small, but not
statistically significant, reduction in Tam-R cell growth (Figures
5c and 6a). There was a significant increase, however, in
HRGβ1-mediated Tam-R cell invasion in response to this com-
bination treatment (P < 0.001, n = 3; Figure 6b).
Figure 2
Effects of gefitinib on erbB receptor dimerization patterns and activity of associated downstream signalling elements Effects of gefitinib on erbB receptor dimerization patterns and activity of associated downstream signalling elements. (a) Western blot (WB) analysis 
of phosphorylated epidermal growth factor receptor (p-EGFR), phosphorylated erbB2, phosphorylated tyrosine (Tyr) and total erbB3 protein expres-
sion following immunoprecipitation with total erbB3 antibody in tamoxifen-resistant MCF-7 (Tam-R) cells prior to and following incubation of Tam-R 
cells with gefitinib (1 μM) for 1 hour. (b) WB analysis of total and phosphorylated EGFR, erbB2, AKT and ERK1/2 protein expression in Tam-R cells 
prior to and following incubation with gefitinib (1 μM) for 1 hour. (c) WB analysis of total and phosphorylated EGFR, erbB2 and erbB3 protein 
expression following immunoprecipitation with total EGFR antibody in Tam-R cells prior to and following incubation with gefitinib (1 μM) for 1 hour. 
Tamoxifen (100 nM) was present in all studies. Data are representative of at least three separate experiments.Breast Cancer Research    Vol 9 No 4    Hutcheson et al.
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Effect of LY294002 alone and in combination with 
gefitinib
The PI3K inhibitor LY294002 (10 μM) inhibited basal AKT
activity and significantly reduced cell proliferation (P < 0.01, n
= 6) in Tam-R cells (Figures 5b and 6a), but was without effect
on basal ERK1/2 and invasion in this cell line (Figures 5b and
6b). HRGβ1 promoted ERK1/2 activity, but not AKT activity, in
Tam-R cells in the presence of LY294002 (Figure 5b), and this
promotion was associated with enhanced Tam-R cell growth
equivalent to that seen in response to HRGβ1 alone (Figure
6a). LY294002, however, prevented HRGβ1-induced Tam-R
cell invasion (P < 0.001, n = 3; Figure 6b).
LY294002 in combination with gefitinib reduced HRGβ1-
induced activation of both ERK1/2 and AKT (Figure 5d), and
significantly reduced HRGβ1-induced cell growth (P < 0.05,
n = 6; Figure 6a). Furthermore, the combination of gefitinib
and LY294002 virtually abolished HRGβ1-driven Tam-R cell
invasion (P < 0.001, n = 3; Figure 6b).
Clinical associations
All clinical breast samples examined exhibited tumour epithe-
lial staining for HRGβ1. This staining ranged from barely
detectable to highly positive and was predominantly cytoplas-
mic, although a low level of membrane staining was observed
(Figure 7a). There was no evidence of nuclear staining.
Staining within individual tumours was reasonably homogene-
ous and control sections remained unstained.
Statistical analyses using either the Mann–Whitney U test
and/or the Spearman rank correlation test were applied to all
patient samples to determine the relationships between
HRGβ1 immunostaining and the tumour grade, the survival
time and the oestrogen receptor, EGFR, erbB2, MAPK, AKT,
Figure 3
Effects of HRGβ1 and gefitinib on tamoxifen-resistant MCF-7 cell  growth and invasion Effects of HRGβ1 and gefitinib on tamoxifen-resistant MCF-7 cell 
growth and invasion. (a) Growth and (b) invasive capacity of tamoxifen-
resistant MCF-7 (Tam-R) cells, on day 7 for growth and on day 3 for 
invasion, following treatment with either HRGβ1 (10 ng/ml) or gefitinib 
(1 mM) or a combination of the two agents. Results expressed as the 
mean ± standard error of the mean of triplicate wells and are represent-
ative of at least three separate experiments. **P < 0.01 versus control, 
***P < 0.001 versus control, †P < 0.05 versus gefitinib, †††P < 0.001 
versus gefitinib.
Figure 4
Effects of HRGβ1 and gefitinib on erbB receptor dimerization patterns  and associated downstream signalling activity Effects of HRGβ1 and gefitinib on erbB receptor dimerization patterns 
and associated downstream signalling activity. (a) Western blot (WB) 
analysis of phosphorylated epidermal growth factor receptor (EGFR), 
phosphorylated erbB2, phosphorylated tyrosine (Tyr) and total erbB3 
protein expression following immunoprecipitation with total erbB3 anti-
body in tamoxifen-resistant MCF-7 (Tam-R) cells prior to and following 
treatment with either gefitinib (1 μM) or vehicle control for 1 hour fol-
lowed by HRGβ1 (10 ng/ml) for 5 minutes. (b) WB analysis of total and 
phosphorylated EGFR, erbB2, AKT and ERK1/2 protein expression in 
Tam-R cells prior to and following incubation with either gefitinib (1 μM) 
or vehicle control for 1 hour followed by either HRGβ1 (10 ng/ml) or 
vehicle control for 5 minutes. Tamoxifen was also present in all studies. 
Data are representative of at least three separate experiments.Available online http://breast-cancer-research.com/content/9/4/R50
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Ki-67, menopausal and metastatic status. Appropriate cutoff
or marker status values for cytoplasmic TGFα, nuclear oestro-
gen receptor, MAPK and total membrane EGFR, erbB2 and
erbB3 were as described previously [38-40]. Status values for
phosphorylated membrane erbB2 were based on true cutoff
values where the cutoff value was zero (no detectable immu-
nostaining), whereas for phosphorylated nuclear AKT the
median value was chosen.
Examination of the degree of HRGβ1 immunostaining in all
patients identified no statistically significant correlations
between HRGβ1 expression and the tumour grade, menopau-
sal, nuclear oestrogen receptor, cytoplasmic TGFα, mem-
brane erbB2 and membrane erbB3 status values. Statistically
significant and positive correlations, however, were observed
between total membrane EGFR, phosphorylated membrane
erbB2 and phosphorylated nuclear MAPK status values and
HRGβ1 positivity (Mann–Whitney U test, P = 0.04, P = 0.006,
P = 0.017, respectively; Figure 7b,c). Moreover, application of
the Spearman rank correlation test to these data also indi-
cated a direct correlation between the levels of cytoplasmic
HRGβ1 and phosphorylated nuclear AKT immunostaining (P
= 0.044), as illustrated in Figure 7c. Furthermore, HRGβ1 lev-
els were shown to be significantly higher in tumours from
patients with distant metastatic deposits compared with
tumours from patients with only locally advanced disease
(Mann–Whitney U test, P = 0.013). Using the median as a cut-
off value for HRGβ1 expression, there was also a trend
towards a poorer prognosis for patients expressing higher lev-
els of HRGβ1, although this trend did not reach statistical
significance.
Figure 5
Effects of combining gefitinib with trastuzumab or LY294002 on HRGβ1-driven signalling in tamoxifen-resistant MCF-7 cells Effects of combining gefitinib with trastuzumab or LY294002 on HRGβ1-driven signalling in tamoxifen-resistant MCF-7 cells. Western analysis of 
total and phosphorylated epidermal growth factor receptor (EGFR), erbB2, AKT and ERK1/2 protein expression in tamoxifen-resistant MCF-7 (Tam-
R) cells prior to and following incubation with either (a) trastuzumab (100 nM) or vehicle control for 7 days, (b) LY294002 (10 μM) or vehicle control 
for 1 hour, (c) gefitinib (1 μM), gefitinib in combination with trastuzumab or vehicle control for 7 days, and (d) gefitinib, gefitinib in combination with 
LY294002 or vehicle control for 1 hour, all followed by either HRGβ1 (10 ng/ml) or vehicle control for 5 minutes. Tamoxifen was also present in all 
studies. Data are representative of at least three separate experiments.Breast Cancer Research    Vol 9 No 4    Hutcheson et al.
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Discussion
Despite the clear therapeutic promise of anti-EGFR therapies
in the preclinical setting, with agents such as gefitinib potently
inhibiting growth of a range of human cancer cell lines that
express a functional EGFR, there is increasing evidence –
from both preclinical and clinical studies – of primary/de novo
and acquired resistance to these inhibitors [11-13]. A key
mechanism implicated in resistance to anti-EGFR agents is
activation of the PI3K/AKT signalling pathway either as a result
of loss of phosphatase and tensin homologue function or of
enhanced insulin-like growth factor type 1 receptor activity
[12,15-19]. More recently it has been reported that, in human
MKN7 gastric cancer cells, HRGβ1 can also circumvent the
antiproliferative action of the selective EGFR-TKI CGP59326
through promotion of erbB3/erbB2 heterodimerization and
activation of the PI3K signalling pathway [44]. In the present
study we have, for the first time, examined whether HRGs can
similarly promote erbB3/PI3K/AKT signalling and effectively
circumvent the inhibitory effects of the anti-EGFR agent gefit-
inib on the growth and invasion of an EGFR-positive Tam-R
breast cancer cell line [32].
In agreement with our previous findings, the Tam-R cell line
was found to express erbB3 at high levels, whereas only mini-
mal expression of erbB4 was observed in this cell line [32].
erbB3 expression was localized primarily at the cell mem-
brane, although some cytoplasmic staining for this receptor
was also observed by immunocytochemistry. We also
attempted to assess expression of HRGβ1, a key erbB3 lig-
and, in this cell line by RT-PCR but were unable to detect a
signal. It has previously been reported that MCF-7 cells do not
synthesize HRGs [45], and our findings now indicate that the
inability to generate this ligand is maintained through acquisi-
tion of tamoxifen resistance in this cell line. The lack of any
autocrine release and action of heregulins by the Tam-R cell
line would explain the low levels of erbB3/erbB2 heterodimers
detected under basal growth conditions. Although low levels
of erbB3 activity were also observed under these conditions,
this is a result of the formation of erbB3/EGFR heterodimers –
most probably a consequence of the autocrine release and
action of the EGFR ligand amphiregulin, which we have previ-
ously shown to be synthesized and released by this cell line
[34]. Indeed, this hypothesis is supported by the fact that
basal erbB3 activity could be reduced by treatment of the cells
with the selective EGFR tyrosine kinase inhibitor gefitinib.
Basal erbB4 activity and heterodimerization could not be
detected in these cells (data not shown).
In agreement with our previous findings, treatment of Tam-R
cells with gefitinib (1 μM) blocked the basal phosphorylation
of EGFR, reduced the basal formation of active EGFR/erbB3
heterodimers and inhibited the basal activation of both AKT
and ERK1/2 [32,34,41]. The reduced basal EGFR/MAPK/
AKT signalling activity in response to gefitinib was also asso-
ciated with a significant reduction in both Tam-R cell prolifera-
tion and invasion, again as previously reported, confirming the
central role played by EGFR signalling in this cell line [32,35].
Interestingly, we also found that gefitinib was capable of
reducing phosphorylation levels of erbB2, an observation we
have reported on previously [32]. Gefitinib is highly selective
for EGFR (median inhibitory concentration = 0.033 μM) but
can inhibit erbB2 tyrosine kinase activity with a median inhibi-
tory concentration of approximately 3–4 μM [46]. At a concen-
tration of 1 μM, however, gefitinib should have little direct
effect on erbB2 tyrosine kinase activity in this study. More
recently it has been proposed that gefitinib can indirectly
inhibit erbB2 activity through inducing the formation of inactive
EGFR/erbB2 heterodimers in erbB2-overexpressing BT-474
cells [47]. In agreement with Anido and colleagues [47], we
found that gefitinib promoted the formation of inactive EGFR/
erbB3 and EGFR/erbB2 heterodimers in our Tam-R cells. This
ability of gefitinib to sequestrate erbB2 into an inactive
Figure 6
Effects of drug combinations on HRGβ1-driven tamoxifen-resistant  MCF-7 cell growth and invasion Effects of drug combinations on HRGβ1-driven tamoxifen-resistant 
MCF-7 cell growth and invasion. (a) Growth and (b) invasive capacity 
of tamoxifen-resistant MCF-7 (Tam-R) cells, on day 7 for growth and on 
day 3 for invasion, following treatment with either HRGβ1 (10 ng/ml), 
gefitinib (1 μM), trastuzumab (100 nM), LY294002 (10 μM) or a combi-
nation of these agents. Results expressed as the mean ± standard error 
of the mean of triplicate wells and are representative of three separate 
experiments. Tamoxifen was present in all studies. *P < 0.05, **P < 
0.01 and ***P < 0.001 versus control; ††P < 0.01 and †††P < 0.001 ver-
sus HRGβ1; §P < 0.05 and §§§P < 0.001 versus gefitinib + HRGβ1.Available online http://breast-cancer-research.com/content/9/4/R50
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complex with EGFR thus prevented activation of erbB2
through dimerization with other erbB family members.
A possible consequence of the sequestration of erbB2 and
erbB3 into inactive heterodimers with EGFR is a reduction in
the availability of erbB2 and erbB3 within the cell. Indeed, it
has been reported that basal levels of erbB2/erbB3 het-
erodimers are greatly reduced following treatment of BT-474
breast cancer cells with gefitinib, resulting in a substantial
blunting of response to HRGβ1 treatment [47]. In agreement
with these findings we demonstrated in the present study that
levels of erbB2/erbB3 heterodimers were reduced following
gefitinib treatment in Tam-R cells and that gefitinib prevented
HRGβ1-induced activation of EGFR and ERK1/2 while reduc-
ing HRGβ1-induced activation of erbB2 and AKT in this cell
line. Since this effect on erbB2 and AKT activity cannot be
attributed to the tyrosine kinase inhibitory activity of gefitinib
because erbB3 is kinase dead [48] and, as mentioned previ-
ously, far higher concentrations of this inhibitor are required to
block erbB2 activity, it is more probably a consequence of the
Figure 7
Immunohistochemical staining for HRGβ1 in primary breast cancer specimens Immunohistochemical staining for HRGβ1 in primary breast cancer specimens. (a) Examples of high and low HRGβ1 expression. Scale bars = 20 
μm. (b) Box-plots illustrating cytoplasmic HRGβ1 immunohistochemistry assessed by H-score analysis in membrane (mem) epidermal growth factor 
receptor (EGFR)-negative, erbB2-negative and erbB3-negative primary breast cancer versus membrane EGFR-positive, erbB2-positive and erbB3-
positive primary breast cancer. A significant positive correlation between cytoplasmic HRGβ1 expression and membrane erbB receptor positivity 
was only seen with EGFR (Mann–Whitney U test, P = 0.04). (c) Box-plots illustrating cytoplasmic HRGβ1 immunohistochemistry assessed by H-
score analysis in membrane (mem) phosphorylated erbB2-negative versus membrane phosphorylated erbB2-positive primary breast cancer and in 
nuclear (nuc) phosphorylated ERK1/2-negative versus nuclear phosphorylated ERK1/2-positive primary breast cancer (Mann–Whitney U test, P = 
0.006 and P = 0.017, respectively), and scatter plot illustrating the significant positive correlation between expression levels of nuclear phosphor-
ylated AKT and cytoplasmic HRGβ1 in the same samples (Spearman rank test, P = 0.044).Breast Cancer Research    Vol 9 No 4    Hutcheson et al.
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reduced erbB2 and erbB3 receptor availability due to gefitinib-
induced sequestration with EGFR. It should also, however, be
noted that although HRGβ1 signalling is reduced by gefitinib
treatment in Tam-R cells, this ligand was still capable of pro-
moting the formation of active erbB2/erbB3, activating AKT
signalling and potently driving cell growth.
These findings clearly indicate that although EGFR is the dom-
inant pathway driving growth in Tam-R cells, if this pathway is
blocked then these cells are capable of utilizing alternative sig-
nalling pathways such as the HRGβ1/erbB3/AKT pathway to
circumvent this blockade and to very effectively maintain cell
growth. Such a resistance mechanism to anti-EGFR therapy is
not unique to Tam-R cells as it has also been shown in MKN7
gastric cancer cells that HRGs can overcome the growth
inhibitory actions of the EGFR tyrosine kinase inhibitor
CGP59326 through activation of downstream AKT and
ERK1/2 signalling pathways [44]. It is also important to point
out that although HRGβ1 only partially recovered Tam-R cell
growth in the presence of gefitinib, this ligand fully circum-
vented the blockade of Tam-R cell invasion generated by this
anti-EGFR agent. HRGβ1 signalling therefore appears as
effective as EGFR signalling in driving invasion of Tam-R cells,
suggesting that targeting EGFR in the presence of HRGs will
have minimal effect on the aggressive phenotype of this cell
line.
We next examined the effect of targeting components of the
HRGβ1 signalling pathway in Tam-R cells to assess whether
such a strategy, in combination with gefitinib, would more
effectively reduce growth and invasive capacity. We initially
targeted erbB2 using the monoclonal antibody trastuzumab. It
has previously been demonstrated that combined targeting of
EGFR and erbB2 is more effective than targeting either agent
alone in inhibiting growth of erbB2-overexpressing breast can-
cer cells [44,49-51]. We similarly found, in the present study,
that Tam-R cells demonstrated a small reduction in HRGβ1-
induced erbB2 and ERK1/2 signalling following treatment
with trastuzumab and gefitinib in combination compared with
gefitinib alone. This effect of the combination treatment on
HRGβ1 signalling activity was also associated with a small but
not significant reduction in HRGβ1-driven Tam-R cell growth
when compared with the effects of gefitinib alone. This combi-
nation strategy, however, was without further significant effect
on HRGβ1-induced AKT activity compared with the effects of
gefitinib alone, and induced a substantial and significant
enhancement of, rather than an inhibition of, HRGβ1-driven
Tam-R cell invasion. Targeting erbB2 with trastuzumab in com-
bination with gefitinib to block HRGβ1 signalling therefore had
only a minimal effect on cell growth and also had the potential
to make the cells substantially more aggressive in nature.
Interestingly, a recent phase I–II clinical study assessing the
effect of trastuzumab in combination with gefitinib in patients
with erbB2-overexpressing metastatic breast cancer reported
that the time to progression was shorter for the combination
compared with trastuzumab alone [52]. Furthermore, this com-
bination treatment was shown to increase erbB3 activity in
erbB2-overexpressing breast cancer cells [52]. Taken in con-
junction with the present findings it is possible that HRGβ1/
erbB3-mediated signalling in the presence of trastuzumab and
gefitinib may maintain cell growth and promote enhanced inva-
sive features within the tumour cells, potentially explaining the
reduced time to progression observed in patients receiving
this treatment regime.
A more effective combination therapy that inhibited both
HRGβ1-driven Tam-R cell growth and invasion was gefitinib in
conjunction with the PI3K inhibitor LY294002. Treatment of
Tam-R cells with this combination potently knocked out activa-
tion of both AKT and ERK1/2. These findings, alongside the
inability of trastuzumab and gefitinib to block HRGβ1-induced
AKT activity, would suggest that the PI3K/AKT signalling
pathway is an important mediator of HRGβ1-driven Tam-R cell
invasion and appears to be activated by an EGFR-independ-
ent and erbB2-independent mechanism in these cells. Indeed,
heregulin-induced PI3K/AKT signalling has been implicated as
a dominant signalling pathway driving cell invasion in a range
of breast cancer cells [25,26,28,31]. It should also, however,
be noted that the enhanced invasive capacity of the Tam-R cell
line in response to trastuzumab and gefitinib in combination
was not associated with an increase in AKT activity; indeed, if
anything, AKT activity was slightly reduced in the presence of
the two inhibitors. As we have found that this enhanced
invasive response to HRGβ1 in the presence of both gefitinib
and trastuzumab remains sensitive to inhibition by LY294002
(data not shown), it is therefore probable that other PI3K-
dependent mechanisms are also involved in mediating this
process. Identifying the exact mechanisms involved in the
EGFR/erbB2-independent HRGβ1-mediated activation of
PI3K-dependent signalling and in the enhanced invasive
behaviour in our Tam-R cell line remains a subject of intense
investigation within our laboratory.
Finally, we examined whether the HRGβ1-mediated gefitinib-
resistant mechanism identified in our Tam-R cells may also be
functional within breast tumours by assessing HRGβ1 expres-
sion in a set of 77 breast cancer tissue samples from breast
cancer patients who had received no previous therapies. We
found that all samples expressed predominantly cytoplasmic
HRGβ1, with this staining being highly heterogeneous
between tumour samples. These findings are in agreement
with other reports assessing HRGβ1 expression in primary
breast cancer specimens [23,24], with both of these studies
demonstrating exclusively cytoplasmic staining for this ligand.
Interestingly, in the present study the highest expression levels
of cytoplasmic HRGβ1 were found in patients with tumours
that expressed high levels of membrane EGFR and increased
activity of the EGFR-associated signalling elements, mem-
brane erbB2, nuclear MAPK and nuclear AKT.Available online http://breast-cancer-research.com/content/9/4/R50
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Interestingly, there was no correlation between expression of
cytoplasmic HRGβ1 expression and either membrane erbB2
or erbB3 in these samples. It should be noted that Visscher
and colleagues [23] were unable to identify any correlations
between EGFR and HRG expression in their primary tumour
specimens; however, this may simply reflect the very small
dataset (34 samples) used in the study [23]. A profile of high
EGFR expression and increased activation of downstream
MAPK and AKT signalling pathways, which mimics the expres-
sion profile observed in our Tam-R model, would suggest that
these patients may benefit from anti-EGFR-targeted therapy.
Since HRGβ1 is also highly expressed in these samples, how-
ever, our model would predict that targeting the EGFR with
agents such as gefitinib would not prove effective due to the
ability of HRGβ1 to overcome EGFR blockade and to potently
drive resistant growth and invasion. Indeed, HRGβ1 levels
were also shown to be significantly higher in distant metastatic
versus locally advanced patients, suggesting a possible link
between this ligand and the invasive capacity of tumour cells.
Conclusion
We have demonstrated that HRGβ1 can partially overcome
the inhibitory effects of gefitinib monotherapy on growth and
invasion of tamoxifen-resistant MCF-7 breast cancer cells
through promotion of erbB3/erbB2 heterodimerization and
activation of the PI3K/AKT signalling pathway. Furthermore,
such a mechanism may be functional in the clinical setting as
HRGβ1 is highly expressed in some EGFR-positive breast
cancers, thus providing a possible de novo resistance mecha-
nism to any utilized anti-EGFR therapy. Combination therapy
targeting HRGβ1 signalling alongside EGFR blockade can
enhance the effectiveness of agents such as gefitinib on
growth and invasion; however, the findings with trastuzumab
and gefitinib in combination, where the minimal benefit of
growth inhibition is offset by enhanced invasive capacity, sug-
gest that rather than simply focusing on cell growth we should
also consider other properties of the cancer phenotype if we
are to fully understand the impact of these therapies on the
cancer cell.
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